Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy
Table 3
Primary outcomes (Mean ± SD).
IVC
IVR
IVTA
value
Mean BCVA improvement (ETDRS letters)
(Mean ± SD)
25.10 ± 3.73
26.32 ± 4.06
17.16 ± 2.87
0.337, <0.01, <0.01
Operation time (minutes)
(Mean ± SD)
56.65 ± 6.52
54.89 ± 6.46
77.32 ± 6.36
0.404, <0.01, <0.01
Incidence of iatrogenic retinal breaks (cases, %)
2 (10.0)
2 (10.5)
8 (42.1)
0.958, 0.024, 0.027
Endodiathermy rate (cases, %)
5 (25.0)
6 (31.6)
12 (63.2)
0.659, 0.014, 0.049
Silicone oil tamponade (cases, %)
9 (45.0)
9 (47.4)
15 (78.9)
0.885, 0.029, 0.045
value of IVC versus IVR, IVC versus IVTA, and IVR versus IVTA.
